Recombinant Human NGAL/Lipocalin-2 Protein, Active
Beta LifeScience
SKU/CAT #: BLK-01117P-100UG

Human NGAL on Tris-Bis PAGE under reduced condition. The purity is greater than 95%.
Recombinant Human NGAL/Lipocalin-2 Protein, Active
Beta LifeScience
SKU/CAT #: BLK-01117P-100UG
Collections: High-quality recombinant proteins, Other recombinant proteins
Our products are highly customizable to meet your specific needs. You can choose options such as endotoxin removal, liquid or lyophilized forms, preferred tags, and the desired functional sequence range for proteins. Submitting a written inquiry expedites the quoting process.
Product Overview
Description | Recombinant Human NGAL/Lipocalin-2 Protein is expressed from HEK293 with His tag at the C-Terminus.It contains Gln21-Gly198. |
Purity | > 95% as determined by Tris-Bis PAGE;> 95% as determined by HPLC |
Accession | P80188 |
Target Symbol | NGAL/Lipocalin-2 |
Species | Human |
Expression System | HEK293 |
Tag | C-His |
Expression Range | Gln21-Gly198 |
Mol. Weight | The protein has a predicted MW of 21.64 kDa. Due to glycosylation, the protein migrates to 25-30 kDa based on Tris-Bis PAGE result. |
Form | Lyophilized |
Formulation | Lyophilized from 0.22um filtered solution in PBS (pH 7.4). Normally 8% trehalose is added as protectant before lyophilization. |
Endotoxin | Less than 1EU per ug by the LAL method. |
Activity | Immobilized Human NGAL, His Tag at 0.2ug/ml (100ul/Well) on the plate. Dose response curve for Anti-NGAL Antibody, hFc Tag with the EC50 of 7.8ng/ml determined by ELISA. Contact us for detailed testing images. |
Storage | Reconstituted protein stable at -80°C for 12 months, 4°C for 1 week. Use a manual defrost freezer and avoid repeated freeze-thaw cycles. |
Shipping | Shipped at ambient temperature. |
Gene Background | Acute kidney injury (AKI) is one of the most common complications of various serious conditions, and early diagnosis is therefore critical for the treatment of AKI. Recent evidence demonstrates that neutrophil gelatinase- associated lipocalin (NGAL) is closely associated with AKI. Several experimental and clinical studies have shown that the expression of urine and serum NGAL increases significantly in AKI. NGAL shows potential to be a new effective early biochemical marker of AKI. Further studies are needed to confirm the significant advantages of NGAL in the diagnosis of early AKI and its value in clinical applications. |